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Spreading antibiotic resistance: 
a universal threat
The worldwide emergence of ‘superbugs’ and 
a dry antibiotic pipeline threaten modern soci-
ety with a return to the preantibiotic era, when 
bacterial infections were the primary cause of 
morbidity and mortality [1]. A recent estimate 
indicates that 400,000 people in Europe were 
infected with multidrug-resistant (MDR) bacte-
ria during 2007, with 25,000 attributable deaths 
[2]. In hospitals in both the developed and the 
developing world, the majority of nosocomial 
outbreaks are caused by a small group of patho-
gens (i.e., Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter bau-
mannii, Pseudomonas aeruginosa and Enterobacter 
species, hereafter referred to as the ‘ESKAPE 
bugs’) [3]. These ESKAPE bugs are increasingly 
prevalent and resistant to most of our anti-
microbial agents, threatening patients’ lives and 
confronting society with huge socioeconomic 
costs. To date, MDR pathogens, such as highly 
drug-resistant A. baumannii (often associated 
with military operations in the Middle East [4]), 
NDM-1-producing Enterobacteriaceae [5], pan-
resistant P. aeruginosa clones [6] and methicillin-
resistant S. aureus (MRSA) [7], have been mostly 
associated with hospital outbreaks. 
In addition, community-associated MRSA 
infections and specific Escherichia coli out-
breaks demonstrate that the community as 
a whole is increasingly threatened by virulent 
anti biotic-resistant pathogens. Community-
associated MRSA infections arise in other-
wise healthy individuals and are more viru-
lent and transmissible than are traditional 
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The worldwide emergence of ‘superbugs’ and a dry antibiotic pipeline threaten 
modern society with a return to the preantibiotic era. Phages – the viruses of 
bacteria – could help fight antibiotic-resistant bacteria. Phage therapy was first 
attempted in 1919 by Felix d’Herelle and was commercially developed in the 
1930s before being replaced by antibiotics in most of the western world. The 
current antibiotic crisis fueled a worldwide renaissance of phage therapy. The 
inherent potential of phages as natural biological bacterium controllers can only 
be put to use if the potential of the coevolutionary aspect of the couplet 
phage–bacterium is fully acknowledged and understood, including potential 
negative consequences. We must learn from past mistakes and set up credible 
studies to gather the urgently required data with regard to the efficacy of phage 
therapy and the evolutionary consequences of its (unlimited) use. Unfortunately, 
our current pharmaceutical economic model, implying costly and time-consuming 
medicinal product development and marketing, and requiring strong intellectual 
property protection, is not compatible with traditional sustainable phage therapy. 
A specific framework with realistic production and documentation requirements, 
which allows a timely (rapid) supply of safe, tailor-made, natural bacteriophages 
to patients, should be developed. Ultimately, economic models should be 
radically reshaped to cater for more sustainable approaches such as phage 
therapy. This is one of the biggest challenges faced by modern medicine and 
society as a whole.
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hospital-associated MRSA strains [8], and the 
recent outbreak of enteroaggregative Shiga toxin/
verotoxin-producing E. coli strain O104:H4 in 
Germany [9] caused over 4000 cases of diarrhea 
– 3167 without hemolytic–uremic syndrome 
(16 deaths) and 908 with hemolytic–uremic syn-
drome (34 deaths) [10]. These cases demonstrate 
that infectious agents are not confined to hospi-
talized patients, but are actually deeply settled 
in our environment. 
For rapidly evolving, genetically versatile bac-
teria such as Pseudomonas, it has turned out to be 
quite easy to develop mechanisms to avoid the 
toxicity of antibiotics, which have remained more 
or less ‘static’ for the last decade. More reflection 
on the biological role of antibiotics in nature as 
secondary metabolites would have revealed that 
resistance evolution was inevitable. Also, in 
nature, bacteria are constantly outsmarting tox-
ins produced by competitors. However, the dif-
ference is that these natural competitors in turn 
react by selection towards adjusted toxins. The 
biological phenomenon of antibiotic resistance is 
typically an emergent characteristic of a dynamic, 
highly complex and self-organizing system that 
evolves at the edge of chaos [11,12]. Moreover, the 
rate of resistance evolution has been exacerbated 
by the overuse and misuse of antimicrobial agents 
in both clinical and agricultural contexts [13–15]. 
Due to the complexity of the antibiotic resis-
tance issue and the immense research and devel-
opment costs and time-frames of developing new 
antibiotics, for which resistance will inevitably 
occur, the pharmaceutical industry is not keen 
to continue with the development of new mol-
ecules. Moreover, even if pharmaceutical com-
panies succeed in developing and marketing 
highly active antibiotics, authorities, sensitized 
by past experiences concerning the rapid emer-
gence of resistance, are likely to withhold these 
new antibiotics as third-line last-rescue drugs, 
thereby limiting the market and consequently 
the commercial interest of the pharmaceutical 
companies. As the industry antibiotic pipeline 
is virtually dry and infectious diseases – major 
causes of morbidity and mortality – are steadily 
on the increase, new initiatives are urgently 
needed.
Phage therapy
Could (bacterio)phages, the viruses of bacteria, 
help fight antibiotic-resistant bacteria [16–18]? A 
virus is a natural biological entity, consisting 
in essence of a molecular assemblage of nucleic 
acids (the genome) surrounded by proteins, 
that behaves as a genetic replicative parasite. 
Lytic phages attach to receptors on the sur-
face of bacteria, inject their genetic material 
through the bacterial membrane and take over 
the bacterium’s transcription and translation 
machinery to synthesize new phages. Finally, 
the bacterial cell wall is destroyed (lysed), releas-
ing the newly assembled virions to the environ-
ment, where they can invade new bacteria. 
Importantly, phages are able to infect bacteria 
regardless of their susceptibility to antibiotics. 
Wherever bacteria are present, there are bound 
to be phages, generally in an order of magnitude 
higher than bacteria. With an estimated unit 
number of 1031, phages are the most abundant 
biological lifelike constituents of our biosphere 
[19–21]. In fact, one could say that we live in an 
ocean of phages. But this does not automati-
cally mean that all phages are safe at therapeutic 
concentrations. No phage-related nucleic acid 
sequence can be found in our genome, unlike 
the huge amount of human endogenous retro-
viral sequences, which make up 8–10% of the 
human genome [22,23]. Some phage-related poly-
merase gene sequences were identified in human 
mitochondrial DNA. It is common knowledge 
that mitochondria originated from Rickettsia-
like ancestor bacteria that started a symbiotic 
relationship with prototype eukaryotic cells [24]. 
Phage DNA was likely introduced in the bac-
terial phase of the mitochondrion, at the time 
when the evolutionary split occurred between 
the prokaryotes and eukaryotes (endosymbiotic 
era), and does not constitute evidence for recent 
DNA exchange. Moreover, recent work suggests 
that even the eukaryotic nucleus itself is a viral 
import [25]. It is possible that phage sequences 
did enter the human genome, but were lost over 
time. In addition, entry into our germline may 
be irrelevant to the potential for causing harm, 
and we do not know how often phage DNA 
integrated into human somatic cells. One must 
also consider that the potential adverse effects of 
phages might not be caused by them acting as 
viruses. Researchers from the Hirszfeld Institute 
of Immunology and Experimental Therapy in 
Poland found phages to be constantly present 
in human and animal bodies [26], where they 
were shown to modulate immune functions [27] 
and interact with cancer cells [28]. It is virtually 
impossible for a phage to enter directly into a 
eukaryotic cell system and subsequently mul-
tiply since it requires prokaryotic-specific cell 
wall receptors and biochemical machinery for 
its attachment and replication (e.g., prokary-
otic polymerases and tRNAs). However, we 
should also consider indirect ways for phages 
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to enter eukaryotes, no matter how far-fetched 
they may be. For example, theoretically, a phage 
could integrate into a plasmid, which could then 
transfer from a bacterium to a eukaryote. 
According to most supporters, however, phage 
therapy has been proven safe through the massive 
application of lytic bacteriophages in humans 
in the past. We conclude that, although there 
are indications that phages are not harmful for 
eukaryotic organisms, more research is needed.
Today, a few laboratories and small and 
medium enterprises are developing phage 
cocktails or phage-based products for the 
treatment of bacterial infection [29]. This anti-
bacterial therapeutic approach was first pro-
posed by Felix d’Herelle almost a century ago. 
The first therapeutic application of phages 
probably occurred as early as 1919 in Paris, 
where d’Herelle used phages to treat patients 
suffering from bacterial dysentery [30]. Later, 
he founded the Laboratoire du Bactériophage 
in Paris, which produced five phage prepara-
tions for commercial use. They were marketed 
by the French company Robert et Carrière, 
which later was acquired by L’Oréal [31]. In 
the USA in the 1930s, pharmaceutical giants 
like Eli Lilly, Squibb & Sons (today Bristol-
Myers Squibb) and the Swan–Myers division 
of Abbott Laboratories started marketing sev-
eral phage preparations. Scientific uncertainties 
and the discovery and widespread marketing of 
antibiotics, however, relegated phage therapy 
to the history books in the western world. As 
such, the current ‘knowledge’ of the therapeu-
tic effect of phages is mainly based on theo-
retical grounds, basic laboratory observations, 
animal models [32–37], safety studies in healthy 
humans [38,39] and decades of empirical medi-
cal experience [31,40–43]. These empirical data 
were mainly accumulated in the former Soviet 
Union and its eastern European satellite states, 
with an important role for the Eliava Institute 
of Bacteriophage, Microbiology and Virology 
in Tbilisi (Georgia), several institutes in 
Russia and the Hirszfeld Institute in Wroclaw 
(Poland). Phage therapy remained a valid ther-
apeutic component in France until the early 
1990s [44]. Unfortunately, the historical clini-
cal data are not taken into account by regula-
tors because it has not been validated accord-
ing to current western regulatory standards. 
The emergence of MDR bacteria has caused a 
renewed interest in phage therapy in western 
Europe and the USA, as illustrated by an expo-
nential increase in phage therapy-related papers 
in the medical literature (Figure 1). 
Phages: not your regular medicinal 
products
Phages can be seen as bacteria’s natural infec-
tious agents. Up to 50% of bacterial mortal-
ity is thought to be due to phage-induced lysis 
[45]; hence, phages impose strong selection for 
bacteria resistance. However, lytic phages can 
only propagate by infecting and lysing bacteria, 
hence there is strong selection to overcome this 
resistance. This interaction leads to antagonistic 
coevolution, consisting of the repeated emergence 
of new phage infectivity and bacterial defense 
mutations [46–50]. Typically, coevolution results 
in continual increases in bacteria resistance and 
phage infectivity ranges, although recent work, 
including a study following real-time coevolu-
tion in soil [51], suggests that high costs associ-
ated with resistance may instead result in differ-
ent, rather than greater, resistance mechanisms 
being selected through time [48,52]. In principle, 
coevolution between bacteria and phages could 
therefore allow the continual production of 
highly infectious phages that can overcome com-
mon bacterial defense mechanisms. However, it 
is important to emphasize that not all phages 
are lytic. Many integrate into bacterial genomes, 
and are propagated via bacterial reproduction 
[53]. Such lysogenic phages will themselves 
coevolve with each other [54], with bacteria and 
with other lytic phages, and the consequences 
of this for phage therapy are currently unclear. 
A recent study showed that in vitro coinfection 
of Pseudomonas fluorescens with multiple phages 
had no net effect of accelerating or slowing down 
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Figure 1. PubMed search results for ‘phage therapy’ or ‘bacteriophage 
therapy’ across time periods. 
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adaptation to the host through between-parasite 
conflict in the system [55]. It is thus tempting 
to speculate that phages act as ‘evolving anti-
biotics’ during real-time coevolution between 
therapeutic phages and infecting bacteria within 
patients. However, while real-time coevolution 
between bacteria and phages results in continual 
suppression of bacterial densities to some extent 
[51,56], the clinical significance of these relatively 
modest density directions is still unclear [57]. 
Phages do, however, play a major role in control-
ling bacterial densities in natural populations, 
and it is reasonable to assume that coevolution 
plays a role in this. For example, phages appear 
to be key players in ending cholera epidemics. 
Faruque et al. observed that seasonal epidemics 
of cholera inversely correlated with the preva-
lence of environmental cholera phages [58]. The 
removal of phages by conditions such as severe 
flooding might contribute to rendering water 
more conducive to human-to-human transfer 
of Vibrio cholerae. Phage amplification in chol-
era patients during a cholera epidemic likely 
contributed to increased environmental phage 
abundance, decreased load of environmental 
V. cholerae and, hence, the collapse of the epi-
demic. In vivo phage amplification in patients 
and subsequent phage infection in the environ-
ment could thus explain the self-limiting nature 
of seasonal cholera epidemics in Bangladesh [59].
It is clear that therapeutic phages are very dif-
ferent from classical (chemical, molecular) medic-
inal products such as antibiotics. Instead, they 
are natural biological entities that play an impor-
tant role in maintaining equilibrium in bacterial 
populations of ecological environments, includ-
ing humans. Hence, we should not see them as 
conventional stable medicinal products, but more 
as interactive and evolving antibacterial prod-
ucts, which could also be used in combination 
(synergy) with antibiotics [60]. The coevolutive 
aspect of the phage–bacterium couplet, which is 
essential for sustainable phage therapy, is often 
neglected.
However, there are potential negative conse-
quences of this coevolutionary potential. For 
example, coevolution has been shown to drive 
the evolution of bacterial mutation rates in labo-
ratory populations of the bacterium P. fluorescens. 
A quarter of the bacterial populations coevolving 
with phages had rapidly (i.e., in less than 200 
generations) acquired mutations that resulted 
in ten- to 100-fold increases in mutation rates, 
whereas no significant change in mutation rates 
was observed in the absence of phages [61]. Given 
the increase in evolvability of mutator bacteria 
(e.g., elevated rates of resistance evolution to anti-
biotics), evolvable phages may have unknown net 
consequences on disease severity. Phage therapy 
should not be implemented widely and without 
limitation, without first determining these con-
sequences through real-time experimental evolu-
tion studies. In the end, natural phages could 
prove useful, but maybe only in specific (niche) 
clinical contexts and under certain conditions 
(e.g., dosage). 
Phage therapy fits well in the emerging field 
of Darwinian medicine (in contrast to a clas-
sical mechanistic – man as a machine – view) 
[62,63], whereby the insights into evolution are 
fully taken into account, but it is less compatible 
with our actual western drug development and 
marketing model.
Hurdles in the current medicinal product 
development & marketing model
This section discusses the problems encountered 
when trying to reintroduce traditional phage 
therapy in modern medicine. 
An analysis of the current European regula-
tory framework [64] and multiple discussions with 
experts and the relevant competent authorities 
revealed that, although the development and 
marketing of phage medicinal products (includ-
ing good manufacturing practice production, 
preclinical and Phase I, II and III clinical trials 
and centralized marketing authorization) is tech-
nically possible, in practice it is not compatible 
with traditional (sustainable) phage therapy [65]. 
The cost of conventional medicinal 
product development & marketing 
(millions of Euros) necessitates strong 
intellectual property protection, but 
today, for natural phages, this protection 
is fragile
Recently, the ruling in a US court in a case 
between the Association of Molecular Pathology 
and the US Patent and Trademark Office invali-
dated seven patents claiming genes and genetic 
diagnostic methods held by Myriad Genetics [66]. 
Although related to genes, this decision opens the 
discussion about the ability to patent naturally 
occurring organisms such as phages. 
In patent law, an invention is considered to be 
new if it is not part of the state of the art. This 
means that a phage or a phage cocktail claimed 
in a patent should never have been isolated or 
produced before. The literature with respect 
to phages as natural entities to treat human 
bacterial infections is enormous. In addition, 
clinical studies using phages performed in 
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the eastern part of Europe have recently been 
translated into English (e.g., [40]). Therefore, 
many natural phages and their uses have been 
disclosed over the past century. European law 
allows the patenting of known substances, such 
as natural phages, for use in a medical method, 
provided that such use is new, meaning that 
such use may not be comprised in the state of 
the art. In the USA, several patents for phages 
used in the food sector were granted, such as 
US7507571 (food additive), claiming “an iso-
lated bacteriophage of a bacteriophage strain 
selected from a [specific] group, [somewhere] 
deposited under a [specific] accession number, 
together with variants thereof, wherein said 
variants retain the phenotypic characteristics of 
said deposited bacteriophages and wherein said 
bacteriophages, and variants thereof, have lytic 
activity against Listeria monocytogenes strains” 
[67]. More important for therapeutic use is the 
US patent 7459272 of Intralytix, Inc., claim-
ing “a method for reducing the risk of bacterial 
infection or sepsis in a person colonized with 
pathogenic bacteria comprising treating the 
colonized person with a pharmaceutical com-
position containing bacteriophage of one or 
more strains which produce lytic infections in 
said pathogenic bacteria.” In 2001, a European 
patent application (EP1250143 A2) was filed, 
claiming “a method for reducing the risk of bac-
terial infection or sepsis in a susceptible patient 
by treating the susceptible patient with a phar-
maceutical composition containing bacterio-
phages of one or more strains which produce 
lytic infections in pathogenic bacteria,” but 
this application was withdrawn in 2004. Only 
recently, “a method for production of compo-
sitions of bacteriophages” was claimed in the 
USA by Phage Biopharm, LLC (US7588929). 
No European counterpart has been published 
yet. Another interesting patent is the US patent 
7758856 (Biocontrol, Ltd) claiming “a compo-
sition for treating a bacterial biofilm,” as well 
as “a method for treating a biofilm infection.” 
A similar patent owned by the UK Health 
Protection Agency has been granted in Europe 
(EP1587520 B1). 
Diverging views between Europe and the USA 
exist on the patenting of biological material. 
Next to the requirements of novelty, inventive 
steps and industrial applicability (which are the 
same for Europe and the USA), in order to be 
patentable in Europe, a certain technical inter-
vention is needed to isolate the phage from its 
natural environment, and the isolated phage 
needs to be properly characterized. However, 
this ‘technical intervention’ has basically been 
known since the 1920s, and the requirement that 
the phage ‘needs to be well characterized’ seems 
obvious and is technically not particularly hard 
to meet [68]. In the USA, phages claimed in a 
patent need to have markedly different charac-
teristics from their counterparts found in nature. 
But, for natural exclusively lytic phages – our 
object of concern here – they simply are the ones 
found in nature. It seems as if only genetically 
modified phages can agree with the US state-
ment. While ‘manipulated’ or engineered phages 
certainly have potential applications (which are 
patentable), given the growing public concern 
and awareness over the potential health and 
environmental risks of genetically modified 
organisms, they are unlikely to obtain licensing 
approval in the near future.
Phage-encoded proteins such as cell wall-
degrading endolysins [69] will be marketed a 
few years from now in the food industry, the 
veterinary field and possibly in medicine. They 
will select resistance, but presumably and 
hopefully at a slower pace than antibiotics. Of 
course, these phage-derived products are not 
capable of self-replicating and evolving in the 
infectious site. 
In this paper, we focus on natural phages sim-
ply because of their natural intrinsic bacterial 
coevolutionary aspect making them suitable for 
flexible therapeutic applications. Patents claim-
ing natural phages are fragile, and ‘inventing 
around’ (making an invention that accomplishes 
the same thing as the original patented invention 
but does not infringe the patented invention) 
also seems to be very difficult [70].
These intellectual property (IP) issues do 
not stimulate investment (of venture capital), 
for the actual paradigm is ‘no IP protection, 
no investment’. However, the renewed interest 
in natural phages as therapeutic agents might 
trigger scientists’ and entrepreneurs’ creativity 
in defining the contours of appropriate patent 
claims for phages or, even better, because there 
are good reasons for not patenting certain natu-
ral substances, considering a new kind of IP 
instrument. New ideas on IP protection should 
not be based on the existing classical model, 
but on a broader ‘new’ philosophy in relation 
to sustainable economic and industrial develop-
ment, as advocated by Petrella and Sachs [71,72]. 
Petrella states that, today, “being competitive” is 
no longer a tool for increased development, but 
an aim in itself [71]. This increasingly implies 
that the possession of patents, often as strategic 
weapons, is more important (in the short term) 
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than owning a truly functional innovative tech-
nology. This kind of attitude tends to block the 
development of new approaches such as phage 
therapy. The patent tragedy is indeed exempli-
fied by the millions of AIDS victims who died 
while drug treatments existed and raises deep 
questions about global IP rights. How can the 
benefits of a global patent system that provides 
incentives for innovation and continuous devel-
opment be combined with an assurance that 
the targeted people (rich and poor) gain access 
to the medical care they need and have rights 
to [73]? 
Therefore, the Group of Lisbon, led by 
Petrella, proposed an evolution to world coop-
erative governance, which is based on a global 
contract that requires that each decision should 
be linked to the fact that each person should 
have access to basic livelihoods [71], including 
health access, which is actually often blocked 
by our outdated economic model. As such, 
phage therapy could be developed under the 
umbrella of, for example, the WHO. The 
WHO recognizes the importance of the world-
wide antibiotic resistance issues [101] and is dis-
cussing new incentives to push the pharma-
ceutical industry to launch new research and 
development projects. Could phage therapy be 
one of them?
The time frames for conventional 
medicinal product development  
& marketing (years) are not 
compatible with a flexible, 
tailor-made & sustainable phage 
therapy concept
Phage therapy depends upon safe and well-
defined phages, but is it really necessary to 
produce and market them in the same way as 
conventional medicinal products? 
In 2009, a phage cocktail, BFC-1, which tar-
geted the most prevalent MDR P. aeruginosa 
and MRSA bacteria in the burn wound cen-
ter of the Queen Astrid Military Hospital in 
Brussels (Belgium), was produced. The cocktail 
consisted of two phages against P. aeruginosa 
and one against S. aureus. It was produced on 
a small scale and in concordance with certain 
relevant quality and safety standards (e.g., ste-
rility, apyrogenicity, pH, adequate shelf life and 
stability). In addition, the phages were shown 
to be exclusively lytic and were characterized at 
the genomic and proteomic level. This specific 
production process was published in 2009 by 
Merabishvili et al. [68]. As the authors did not 
consider phages to be conventional medicinal 
products, the phage cocktail was not produced 
in concordance with the requirements of the EU 
medicinal product regulation. After approval 
by a leading Medical Ethical Committee (of 
the Free University of Brussels), phage cock-
tail BFC-1 was applied in a small pilot study 
in the burn unit of the Queen Astrid Military 
Hospital in Brussels. This small trial was dis-
cussed in a recent review by Kutter and col-
leagues [43]. No adverse events or side effects 
were observed. 
However, the European Commission stated 
recently that EU’s legislation on medicinal 
products does not define specific requirements 
related to bacteriophage therapy or medicines 
composed of bacteriophages because it consid-
ers that the existing regulatory framework is 
adequate for bacteriophage therapy. There is 
thus no need for a specific set of documentation 
for bacteriophage therapy [74]. We do not share 
this opinion for the reasons discussed below. 
To exploit the main advantage of phages 
over classical ‘static’ drugs such as antibiotics, 
and more specifically their capacity to rapidly 
(in a matter of days to weeks) evolve to target 
emerging (phage-resistant) pathogenic bacterial 
strains, phage cocktails should not be submit-
ted to the conventional long medicinal product 
development and licensing pathway. Even if the 
EMA would eventually adapt its rules in a simi-
lar manner to what they did for updated seasonal 
influenza vaccines, which are annually licensed 
[75], development times of many months are still 
much too long in view of the enormous chal-
lenges related to rapidly progressing bacterial 
resistance. The real power of phage therapy lies 
in the fact that the search for a potent natural 
phage and the preparation of a classic galenic 
preparation (e.g., physiological water or a basic 
ointment) containing phages is practically fea-
sible in the time frame of days to weeks. In tra-
ditional phage therapy, new therapeutic phages 
are usually selected from environmental sources 
such as raw sewage water or isolated from clini-
cal specimens from infected patients (Figure 2). 
Georgian and Polish phage therapy centers are 
keeping extensive therapeutic phage collections, 
which are regularly enriched with new phages, 
thus widening the host range of the collection. 
Ineffective phages can be ‘trained’, a term indi-
cating the in vitro selection of phage mutants 
that exhibit an increased infectivity range. As 
such, it is possible to obtain potent lytic phages 
against problematic enteroaggregative E. coli 
strains [76] in a matter of days, for example. 
Theoretically, they could thus have been used to 
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help control the O104:H4 outbreak that caused 
the death of 50 patients in Germany [9,10]. In 
this context, an O104:H4 phage preparation 
that takes months to years to develop, produce 
and register is ineffective. As phages are species- 
and often even strain-specific, it is very likely 
that current O104:H4-specific phage prepara-
tions will not be active against future epidemic 
enteroaggregative E. coli strains. Provided that 
future problematic bacteria are broadly known, 
some ‘broad-spectrum’ cocktails could be devel-
oped in advance and used as the first-line answer 
to acute healthcare problems (e.g., bioweapons). 
Some cocktails will inevitably fail due to the 
greater biodiversity outside of the laboratory, 
and the ones that initially work will need to 
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Figure 2. Two phage therapy concepts. IP issues may hamper pharmaceutical companies in the worldwide marketing of generic 
phage preparations. The long and expensive regulatory pathways form insurmountable obstacles for eventual nonprofit phage therapy 
centers or SMEs, which opt for a tailor-made concept, and for institutions that would like to use inexpensive phages for commercially 
unattractive applications (e.g., in developing countries) [65].
GMP: Good manufacturing practice; IP: Intellectual property; SME: Small and medium enterprise.
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be regularly updated due to the emergence of 
resistance. In a recent study, it was shown that 
P. aeruginosa challenged in vitro with a cocktail 
of four potent phages swiftly developed resis-
tance to all four phages [Hall AR, De Vos D, Friman 
VP, Pirnay JP, Buckling A. Effects of sequential and simul-
taneous application of bacteriophages on populations of 
Pseudomonas aeruginosa in vitro and in waxmoth larvae 
(2012), Submitted]. We are currently discussing our 
viewpoint with EMA’s Innovation Task Force 
(ITF). The ITF has the competence to facilitate 
the informal exchange of information and the 
provision of guidance early in the development 
process of medicinal products. Our objectives 
are to develop a specific framework (e.g., realistic 
production and documentation requirements) 
that allows a timely (rapid) supply of tailor-
made productions of natural bacteriophages to 
patients.
Responsible & sustainable phage 
therapy is not compatible with current 
pharmacoeconomic models 
Acceptable IP protection and development and 
licensing procedures were available for antibi-
otics. They did not prevent the overuses and 
misuses that gave rise to the current antibiotic 
resistance crisis. Solving the aforementioned IP 
and development issues will thus not necessarily 
lead to rational and sustainable phage therapy. 
The question is, how can responsible and lim-
ited use be promoted? It is very doubtful that 
this will be compatible with actual economic 
incentives. Even world cooperative governance 
will provide no guarantees, as the primary 
goal of organizations such as the WHO is to 
limit infections, not to support sustainable 
approaches. 
It is our opinion that, ultimately, economic 
models will need to be radically reshaped in 
order to cater for more sustainable approaches 
such as phage therapy. 
Current state
The tailor-made approach and sustainable 
nature of traditional phage therapy and IP 
issues may hamper pharmaceutical companies 
in the worldwide marketing of generic phage 
preparations. Nonprofit/public institutions 
such as (university) hospitals that would like 
to develop flexible and sustainable tailor-made 
(i.e., to an outbreak) phage therapy and are 
not necessarily disheartened by the IP issues 
and the subsequent uncertainty of large profits 
are generally unable to generate the necessary 
funding. In addition, the prescribed medicinal 
product development and licensing pathways 
cancel the advantages of phage therapy over 
antibiotics. It is thus difficult to reconcile a 
flexible and sustainable phage therapy concept 
with the current (western) medical and phar-
maceutical environment (Figure 2). As a result of 
this conundrum, only local and sporadic phage 
applications have been performed in the west-
ern world to date, often based on individual 
approval governed within the ‘Declaration of 
Helsinki’ framework [102]. In Poland, an EU 
member state, a specific national adaptive regu-
lation, based on the Declaration of Helsinki, 
was issued to regulate phage therapy. A medi-
cal doctor is allowed to apply phage therapy 
where proven therapeutic methods do not exist 
or have been ineffective (e.g., in MDR infec-
tions) and provided that the patient or their 
legal representative gives informed consent. In 
France, Alain Dublanchet, a veteran of phage 
therapy, occasionally applies phages in hope-
less osteomyelitis cases [65]. In Australia, phage 
therapy was recently applied under the umbrella 
of ‘compassionate use’ for the successful treat-
ment of refractory P. aeruginosa urinary tract 
infection in a cancer patient [77]. 
Conclusion
Phages are not straightforward inanimate and 
stable substances, but evolvable and natural 
biological entities. Future sustainable phage 
therapy concepts should fully acknowledge the 
potential of the coevolutionary aspect of the 
phage–bacterium couplet. Only then can the 
inherent potential of phages as natural biologi-
cal bacterium controllers be put to use. Indeed, 
bacteria will inevitably become resistant to 
phages, but due to the continuously ongoing 
arms race/competition between the two pro-
tagonists, specific phages that are able to infect 
the formerly resistant bacterial strains can be 
expected to quickly emerge. However, more 
experimental evolution studies are necessary to 
determine the potential negative evolutionary 
consequences of unlimited phage therapy. 
The existing pharmaceutical regulatory 
framework and business models are not com-
patible with a dynamic and sustainable phage 
therapy concept. The actual economic models 
reduce pharmaceutical companies to ‘com-
mon button’ producers neglecting their main 
societal role: providing people with adequate 
products for better health. Therefore, a suitable 
environment for phage therapy should be devel-
oped. Fundamental changes of mentality in the 
medical and pharmaceutical environment (e.g., 
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towards patentability and restrictive licensing) 
are essential for a successful introduction of 
phage therapy in modern (future) medicine. 
We need to radically reshape our (pharmaceuti-
cal) economic models to cater for more sustain-
able approaches that are beneficial for human 
survival. 
Phage therapy fits well in the new emerg-
ing field of Darwinian medicine, where the 
insights of evolution are fully taken into 
account. Viruses, among which are phages, 
were involved in the origin of life itself and 
play a major role in biological evolution [78–
82]. Hopefully, they will play a role in the 
future control of bacterial disease. We con-
sider our plea for a more realistic approach to 
phage therapy, which takes into account the 
coevolutionary aspect of the bacterium and 
its phage, to be scientifically sound. We must 
learn from the errors that contributed to the 
rise of antibiotic resistance. We hope to foster 
this vision in collaboration with the competent 
authorities and responsible economic actors, 
as only a common effort will make it a (direly 
needed) reality.
Future perspective
In the short term, we predict the setting up of 
credible studies to gather the required data with 
regard to the efficacy and evolutionary conse-
quences of phage therapy. These studies could 
be chaperoned by health protection agencies 
such as the European CDC. 
In the medium term, we predict the develop-
ment of a specific framework, in collaboration 
with the EMA’s ITF (or with the US FDA), 
with realistic production and documentation 
requirements that allow a timely supply of safe, 
tailor-made natural bacteriophages.
In the long term, we predict the radical 
reshaping of our (pharmaceutical) economic 
models to cater for more sustainable approaches. 
Phage therapy could be developed under the 
umbrella of the WHO.
Executive summary
Spreading antibiotic resistance: a universal threat
 n Overuse and misuse of antibiotics caused the emergence of organisms that are resistant to these medicinal products, leading to 
increased morbidity and mortality and increased healthcare costs. 
 n Because new antibiotics have become of limited use and are thus less profitable, pharmaceutical companies are reluctant to invest in 
the research and development of new antibiotics. 
Phage therapy
 n Phage therapy – the use of the viruses of bacteria to fight bacterial infection – was first advocated by Felix d’Herelle in 1919. 
 n Due to the advent of antibiotics and scientific controversies, phage therapy was abandoned in the western world. 
 n The current antibiotic resistance crisis has caused a renewed interest in phage therapy.
Phages: not your regular medicinal products
 n Phages are very different from classical (chemical molecular) medicinal products.
 n Phages are natural biological entities that coevolve with and control bacteria in the environment, including humans, which is the basis 
of sustainable phage therapy.
 n There might also be potential negative consequences of bacterial phage coevolution.
Hurdles in the current medicinal product development & marketing model
 n When trying to introduce traditional sustainable phage therapy in modern medicine, one is confronted with three issues:
– The cost of conventional medicinal product development and marketing (millions of Euros) necessitates strong intellectual property 
protection, but today, for natural phages, this protection is fragile;
– The time-frames for conventional medicinal product development and marketing (years) are not compatible with a flexible, 
tailor-made and sustainable phage therapy concept;
– Responsible and sustainable phage therapy is not compatible with current pharmacoeconomic models.
Current status 
 n Only local and sporadic phage applications are performed in the western world, often based on individual approval governed within 
the ‘Declaration of Helsinki’ framework.
Conclusion
 n Future sustainable phage therapy concepts should fully acknowledge the potential of the coevolutionary aspect of the phage–bacterium 
couplet.
 n More research is needed to determine the potential negative coevolutionary consequences of unlimited phage therapy. 
 n Our (pharmaceutical) economic models need to be radically reshaped to cater for more sustainable approaches that are beneficial for 
human survival.
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